GLP-1 Drugs and Kidney Fibrosis in Mice

A paper published in iScience on 18 September 2026 compared three GLP-1-class drugs, semaglutide, tirzepatide and retatrutide, on kidney scarring in mice^[1]. The title says exactly what the paper is: a comparative study in mice. It used two rodent models, a surgically obstructed kidney and separately an aging mouse, plus human kidney cells grown in a dish. Nothing here was tested in a person, and nothing here shows that semaglutide, tirzepatide or retatrutide prevent or treat kidney fibrosis in humans.

That distinction is worth holding onto because kidney health is already a live human question for this drug class. Semaglutide picked up an FDA-approved kidney indication in January 2025, built on a large randomized trial in people with type-2 diabetes and chronic kidney disease^[2]. Below: what the new mouse paper found, how it relates to that separate human evidence, and where the animal result stops.

What the study actually did

The research team, based at South-Central Minzu University and the Eighth Affiliated Hospital of Southern Medical University, ran two mouse experiments and one cell experiment^[1]. The first used the unilateral ureteral obstruction model, usually shortened to UUO, in which surgeons tie off one ureter (the tube that drains urine from the kidney) in a mouse. That blocked kidney develops fibrosis on a predictable, fast timeline, which is why UUO is one of the most widely used tools for studying kidney scarring mechanisms in a lab. It is a deliberate injury built to produce a clear signal, not a stand-in for how chronic kidney disease develops in a person over years.

The second used naturally aged mice rather than a surgical injury, to look at fibrosis that accumulates with age instead of fibrosis forced by an obstruction. Alongside both mouse models, the team tested the same three drugs on HK-2 cells, a standard line of human kidney tubule cells grown in a dish, to see whether the drugs acted directly on kidney cells or only through effects elsewhere in the body. None of this is a diabetic-kidney-disease model, and none of it involves a mouse with the drug-induced weight loss and metabolic changes that come with treating an overweight or diabetic person.

What the researchers found

In the obstructed-kidney model, the three drugs looked different from each other at the mechanism level. The authors linked semaglutide's effect to inhibition of a signaling pathway called PI3K-AKT, tirzepatide's effect to that same PI3K-AKT inhibition plus activation of a separate pathway called PPAR, and retatrutide's effect to PI3K-AKT inhibition together with inhibition of a third pathway called NF-kB^[1]. In plain terms: all three drugs touched an overlapping pathway linked to scar-tissue formation, but each one also did something the others did not.

In the aging-mouse model, the picture was more unified. All three drugs were linked to easing a cell-cycle stall called G2/M arrest, a state that kidney cells settle into as they age and that is tied to ongoing fibrosis. Across both mouse models, the paper reports that retatrutide showed the largest effect at the doses tested^[1]. The authors describe their own paper as offering "a framework for understanding the renoprotective actions of these drugs" and as generating "hypotheses for future investigation", not as establishing a treatment effect^[1]. That is the accurate way to read it: an early mechanistic comparison, not a verdict.

Why kidneys and GLP-1 drugs are already a human question

Separately from any mouse data, semaglutide already has a completed, large-scale human trial on kidney outcomes. The FLOW trial randomized 3,533 adults with type-2 diabetes and chronic kidney disease to semaglutide or placebo and reported a 24% reduction in a composite endpoint of kidney failure, a large drop in kidney function, or death from kidney or cardiovascular causes (hazard ratio 0.76)^[2]. On the strength of that trial, the FDA approved semaglutide in January 2025 specifically to reduce the risk of kidney disease progressing in adults who have both type-2 diabetes and chronic kidney disease^[3]. That is a genuinely different category of evidence from the mouse paper: a randomized human trial with a hard clinical endpoint, reviewed and approved by a regulator, for one specific drug and one specific patient population.

Tirzepatide and retatrutide do not have anything equivalent yet. Retatrutide's own kidney and cardiovascular outcomes trial, TRIUMPH-Outcomes, is running in 10,000 participants but is not due to finish until February 2029, and retatrutide itself remains unapproved by the FDA, the EMA or any national regulator PeptideMethods tracks. The new mouse paper is one of the reasons researchers are now curious about kidney effects across the whole drug class, not evidence that the class-wide question has been answered.

What this is not, and what we still do not know

This is not a human clinical trial. It is not evidence that semaglutide, tirzepatide or retatrutide prevent or reverse kidney fibrosis in people with diabetes, obesity or chronic kidney disease. It is not a dosing guide: the amounts given to the mice were experimental exposures set by the research team to produce a measurable effect in a small animal, not a human-equivalent regimen, and nothing about them should be read as a dose recommendation for a person.

It also has not been independently repeated. This is one paper from one research group, and mechanistic findings in a single rodent study routinely fail to hold up when a different lab tries to reproduce them, or when the same molecule is finally tested in people. We do not yet know whether retatrutide's apparent edge over semaglutide and tirzepatide in these two mouse models would show up in a human kidney trial at all, whether the PI3K-AKT, PPAR and NF-kB pathway differences the authors describe hold up under further testing, or whether any of this generalizes beyond the UUO and aging-mouse models used here.

If you take one of these drugs and have kidney disease

This paper is not a reason to start, stop or switch anything. If you have chronic kidney disease and are on semaglutide, the relevant approved evidence is the FLOW trial and the resulting FDA label, and your prescriber already has access to that. If you are on tirzepatide or considering retatrutide, the honest position is that kidney-specific human outcome data for those two does not exist yet. Any decision about your kidneys and your medication belongs in a conversation with the clinician who knows your history and your labs, not in a mouse paper.

This article is for educational and journalistic purposes only and does not constitute medical advice. Semaglutide and tirzepatide are prescription medicines; retatrutide is an investigational compound with no marketing authorization anywhere PeptideMethods covers. Always talk to a qualified healthcare professional before making any decision about a GLP-1-class medicine. PeptideMethods.com does not sell, distribute or facilitate the sale of any peptide product.